Overall Vote Recommendation

Principle Criteria

Free Enterprise

Property Rights

Personal Responsibility

Limited Government

Individual Liberty

Digest

HB 3057 seeks to expand health benefit coverage in Texas to include chimeric antigen receptor (CAR) T-cell therapy, a specialized cancer treatment known for its life-saving potential. The bill mandates that health benefit plans providing medical or surgical coverage include CAR T-cell therapy when it is determined to be medically necessary and administered by a qualified healthcare provider. The goal of the legislation is to ensure that patients requiring this advanced therapy have access to it under their health insurance plans, addressing a critical need for those facing severe medical conditions.

The bill applies to a broad range of health insurance plans, including individual, group, and employer-sponsored plans, as well as those offered by health maintenance organizations (HMOs), nonprofit health corporations, and multiple employer welfare arrangements. Specifically, it covers plans governed by Chapters 842, 843, 844, 846, 884, 885, 941, and 942 of the Texas Insurance Code. However, the legislation explicitly excludes coverage for CAR T-cell therapy under the Medicaid program and the Children's Health Insurance Program (CHIP), recognizing the different funding structures and regulations of these public programs.

To qualify for coverage under the new law, CAR T-cell therapy must meet two specific requirements: it must be deemed medically necessary, and it must be administered by a healthcare provider that is both certified and enrolled in an approved risk evaluation and mitigation strategy (REMS) under federal regulations (21 U.S.C. Section 355-1) and part of the health benefit plan's provider network. This ensures that patients receive care from facilities equipped to manage the risks associated with CAR T-cell therapy. Additionally, the bill directs the Texas Insurance Commissioner to establish any necessary rules to implement these provisions.

The implementation timeline specifies that the new coverage requirements will apply to health plans delivered, issued, or renewed on or after January 1, 2026, with the bill taking effect on September 1, 2025. This phased approach allows insurers and healthcare providers time to adjust to the new requirements. The bill's emphasis on increasing access to cutting-edge medical treatments aligns with ongoing healthcare policy efforts to address patient needs while ensuring safety and regulatory compliance.

The original version of HB 3057 focused on establishing network standards for Chimeric Antigen Receptor T-Cell (CAR T) therapy. It aimed to ensure that if a health benefit plan covered CAR T therapy, the therapy could be administered at any certified healthcare facility that met the FDA's safety and training requirements. The original bill explicitly prohibited health benefit plans from refusing to contract with, or denying coverage for, any CAR T therapy provider that was certified under FDA regulations. This approach prioritized patient access by preventing insurance companies from restricting coverage based on the healthcare provider’s network status, thereby broadening the range of treatment facilities available to patients.

In contrast, the committee substitute shifted focus from network standards to mandating coverage for CAR T therapy itself. The substitute version specifies that health benefit plans that offer coverage for CAR T therapy must include such coverage when it is medically necessary and provided by a healthcare facility that meets FDA certification and risk evaluation and mitigation strategy (REMS) requirements. Additionally, the facility must also be part of the health plan's network, thus retaining the insurer's ability to define their network of approved providers. The substitute does not mandate that insurers contract with all certified providers, unlike the original bill, and focuses instead on ensuring that the therapy is covered when provided within the insurer’s established network.

While the original bill aimed at maximizing access by expanding network flexibility, the substitute bill takes a more conservative approach by ensuring coverage within existing network structures. The change from requiring network inclusion of all certified facilities to allowing insurers to maintain network discretion reflects a shift from patient-centered network access to structured coverage criteria. This likely addresses concerns from insurers regarding the logistics and costs associated with mandatory network expansion.

Author (1)

Brooks Landgraf

Sponsor (1)

Kevin Sparks

Co-Sponsor (1)

Adam Hinojosa

Contact the Author

Rep. Brooks Landgraf

Capitol Phone:

(512) 463-0546

Capitol Office:

EXT E2.602

E-Mail:

[email protected]

Visit Official Website

Fiscal Notes

According to the Legislative Budget Board (LBB) HB 3057 is not expected to have a significant fiscal impact on the state. According to the LBB, any costs associated with implementing the bill's provisions can be absorbed within existing resources. This suggests that state agencies affected by the bill, including those involved in healthcare and insurance regulation, can manage the bill's requirements without needing additional funding or adjustments to their current budgets.

The fiscal note also states that no fiscal implication is anticipated for local governments. This means that counties, cities, and other local entities are not expected to experience additional costs as a result of the bill's implementation. The analysis takes into account the involvement of several state agencies, including the Teacher Retirement System, Employees Retirement System, Department of Insurance, Health and Human Services Commission, Texas A&M University System, and The University of Texas System Administration. These agencies are not expected to face significant financial burdens due to the bill.

In summary, the LBB's assessment highlights that HB 3057 would not substantially increase state or local expenditures. The anticipated costs associated with requiring health benefit plans to cover Chimeric Antigen Receptor T-Cell (CAR T) therapy are considered manageable within the existing infrastructure and resources of the relevant state agencies. This fiscal assessment supports the view that the bill's implementation would be financially sustainable for the state.

Vote Recommendation Notes

HB 3057 aims to mandate that health benefit plans covering Chimeric Antigen Receptor T-cell (CAR T) therapy provide coverage when the therapy is medically necessary and administered by a certified healthcare provider participating in the plan’s network. The bill’s stated purpose is to increase access to this costly but potentially life-saving cancer treatment by allowing more community healthcare facilities to administer the therapy rather than limiting it to major academic centers. The bill is set to take effect on September 1, 2025, applying to health plans delivered, issued for delivery, or renewed on or after January 1, 2026.

While the intention to expand access to CAR T therapy is commendable, several critical issues make a No vote advisable, particularly from a perspective that prioritizes free enterprise and limited government. The bill introduces government intervention into the private health insurance market by mandating specific coverage requirements. This approach conflicts with free market principles by restricting insurers’ ability to negotiate network contracts and select facilities based on cost-effectiveness and quality of care. By mandating that any certified healthcare facility in a plan’s network be eligible to provide CAR T therapy, the bill reduces insurers’ capacity to contain costs through selective contracting with specialized, proven centers.

This mandate could also lead to increased insurance costs as more facilities become eligible to administer this expensive therapy. CAR T treatments can cost hundreds of thousands of dollars per patient, and expanding coverage to additional centers might result in higher claims costs, ultimately raising premiums for all insured individuals. This potential increase in insurance premiums spreads costs across the pool of policyholders, including those who may not need or use such high-cost treatments, which runs counter to the principle of personal responsibility.

Furthermore, the bill risks market distortion by mandating coverage in a way that favors one specific therapy. This could hinder innovation within the cancer treatment market, as private insurers are less able to respond to market demands and more flexible care solutions. An artificial mandate like this one could also reduce incentives for the development of alternative, potentially more affordable, treatments.

Another concern lies in the burden placed on small employers and health plans. The bill applies to small employer health benefit plans, which already face challenges managing healthcare costs. Imposing such mandates could force small employers to reduce benefits or even drop coverage entirely, ultimately limiting employees’ access to affordable health insurance. This would negatively impact individual liberty by reducing consumer choice in health coverage.

From the perspective of limited government, this bill represents an overreach by imposing healthcare coverage standards on private entities. Instead of allowing market-driven solutions to emerge naturally, the state would dictate how insurers must handle coverage, contradicting the principle of minimizing governmental interference in private enterprise.

Lastly, while the bill aims to broaden access to CAR T therapy, it does not guarantee that rural or underserved areas will see substantial improvements. Merely increasing the number of qualifying facilities does not address geographic disparities or the workforce and infrastructure challenges that limit the establishment of new CAR T therapy centers in rural regions. This gap undermines the bill’s primary objective and raises questions about its actual effectiveness in addressing access issues.

In conclusion, while HB 3057 seeks to improve access to an important cancer treatment, it does so at the cost of free enterprise, market stability, and limited government principles. Lawmakers who advocate for market-driven healthcare solutions and reduced government intervention should oppose this bill. A more prudent approach would involve incentive-based policies that encourage private sector innovation and voluntary expansions of CAR T therapy access, rather than imposing coverage mandates on insurers. Texas Policy Research recommends that lawmakers vote NO on HB 3057.

Individual Liberty: The bill potentially infringes on individual liberty by limiting patients' freedom to choose where they receive CAR T therapy. By allowing insurance companies to restrict coverage to specific, network-participating facilities that meet stringent federal certification requirements, the bill could reduce patients' options and force them to travel to approved centers. This could place a burden on those living in rural or underserved areas, limiting their autonomy in healthcare decisions.
Personal Responsibility: The bill may indirectly impact personal responsibility by reducing patients' ability to make healthcare choices based on their unique circumstances. Instead of empowering patients to choose the most convenient or personally preferred treatment center, it confines them to specific network facilities. This limitation on choice reduces individuals’ ability to take charge of their own healthcare planning and decisions, particularly when navigating complex treatment options for serious conditions like cancer.
Free Enterprise: The most significant impact of the bill is on free enterprise. By requiring health benefit plans to cover CAR T therapy only when administered at certified and network-approved healthcare facilities, the legislation could stifle competition. Independent or smaller healthcare facilities that may offer equivalent or even superior care but lack specific certifications or network inclusion may be effectively excluded from providing these treatments. This restriction can hinder market dynamics, as insurance companies are discouraged from contracting with a broader range of providers, potentially resulting in monopolistic practices within the healthcare market.
Private Property Rights: The bill has a limited impact on private property rights, as it primarily affects healthcare providers and insurance companies rather than private property ownership. However, to the extent that healthcare facilities are private enterprises, the requirement to meet specific federal certification standards to offer CAR T therapy could impose additional operational burdens. This may indirectly affect how these private entities manage and utilize their resources.
Limited Government: The bill’s requirements increase government involvement in healthcare by mandating specific insurance coverage standards and specifying the types of facilities that qualify for CAR T therapy reimbursement. By embedding federal certification requirements into state law, the legislation expands regulatory oversight and reduces the flexibility of both healthcare providers and insurers to operate independently. This runs counter to the principle of limited government by embedding more bureaucratic control into healthcare practices.

View Bill Text and Status